Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s): ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Here's an OA drug-failed P2 and misses out on $250M USD

<< Previous

Bullboard Posts

Next >>

Comment by TriumphSpitSixon Oct 19, 2020 10:25pm

272 Views

Post# 31746142

RE:RE:Here's an OA drug-failed P2 and misses out on $250M USD

A $5B USD deal for Antibe's pipeline (each with more promise than any of Galapagos' dogs combined) would put us just under $13 ($17 CAD) per share based on current OS.

File under "Life-changing Financial Events."

bringon10bagger wrote: I guess Antibe's pipeline has some value.......quote from article....With Gilead paying $5 billion upfront to secure broad access to Galapagos’ pipeline,

MrMugsy wrote: I guess it was a high risk venture and failed.

https://www.fiercebiotech.com/biotech/galapagos-osteoarthritis-drug-flunks-phase-2-dashing-hopes-250m-gilead-deal